Clinical Trial Update: Efficacy and Safety of Canakinumab in Schnitzler Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of canakinumab in Schnitzler syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schnitzler Syndrome

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Schnitzler Syndrome | Phase 2 | Status: COMPLETED